For example, phosphorylated NFS1 was found to weaken oxaliplatin-based chemosensitivity of colorectal cancer (CRC) by preventing PANoptosis 12, implicating that the inhibition of NFS1 serves as a promising strategy for improving the outcome of platinum-based chemotherapy-induced PANoptosis in the treatment of CRC. This evidence concerns the gene NFS1 and colorectal cancer.